Примери за използване на Anti-platelet на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Patients with known coagulopathy, on anti-platelet or anti-coagulant therapy.
In general, use of anti-platelet medicines, older age, or a low body weight increase the risk of bleeding.
It is not recommended to take along with thrombolytic anti-platelet drugs and Atecardol tablets.
Kengrexal is an anti-platelet medicine that contains the active substance cangrelor.
OZURDEX should be used with caution in patients taking anti-coagulant or anti-platelet medicinal products.
Treatment may include aspirin or other anti-platelet medications like Aggrenox or clopidogrel(Plavix).
Anti-platelet or other anti-coagulant medicinal products must not be used concomitantly with Glybera at the time of injection.
People in Bristol UK who make use of anti-platelet drugs or blood slimmers must not eat Forskolin.
Anti-platelet medicinal products, such as clopidogrel, were used at some stage during the clinical studies in up to 56% of patients.
People in Austin US who make use of anti-platelet pills or blood slimmers ought to not consume Forskolin.
As well as these lifestyle changes,a doctor can help to reduce the risk of future ischemic strokes through prescribing anti-coagulant and/or anti-platelet medication.
Treatment could embody aspirin or different anti-platelet medications like Aggrenox or clopidogrel( Plavix).
Anti-platelet or other anti-coagulant medicinal products must not be taken for at least one week before the leg injections or one day after the injection(see section 4.3).
Individuals in Charleston US who utilize anti-platelet tablets or blood slimmers ought to not take in Forskolin.
Anti-platelet or other anti-coagulant medicinal products must not be used concomitantly with Glybera at the time of injection and for at least one week before or one day after the injection.
Individuals in Jersey City US that make use of anti-platelet capsules or blood thinners should not eat Forskolin.
Vulnerable patient groups such as patients with severe active infections until complete resolution, uncontrolled hypertension, a history of arterial dissection of the cervicocephalic arteries, of stroke, angina pectoris or myocardial infarction andpatients with known coagulopathy, on anti-platelet or anticoagulant therapy, should be contraindicated.
The possible role of anti-platelet, anti-coagulant or lipid lowering drugs in reducing the risk of vascular occlusive events remains uncertain.
Your doctor may consider prescribing Aggrenox,a combination of low-dose aspirin and the anti-platelet drug dipyridamole, to reduce blood clotting.
If the patient is taking anti-coagulant or anti-platelet medication like Warfarin or Clopidogrel, they can be given drugs or blood transfusions to counter the medication's effects.
Your doctor might also consider prescribing Aggrenox,a combination of low-dose aspirin and the anti-platelet drug dipyridamole to reduce the risk of blood clotting.
If you take warfarin(Coumadin) or anti-platelet drugs such as clopidogrel(Plavix) to prevent blood clots, you may be given drugs or transfusions of blood products to counteract the blood thinners' effects.
You may receive acetylsalicylic acid(ASA)while you are treated with Kengrexal or another type of anti-platelet medicine(e.g., clopidogrel) before and after you are treated with Kengrexal.
If the patient is taking blood-thinning anti-coagulants or an anti-platelet medication like Warfarin or Clopidogrel, they can be given drugs to counter the medication's effects or blood transfusions to make up for blood loss.
Adjuvant treatment in secondary prevention after myocardial infarction,in addition to other standard therapy(e.g. statins, anti-platelet medicinal products, beta-blockers, ACE inhibitors).
Pregnant or lactating women orindividuals taking anticoagulant or anti-platelet medication should consult their doctors before taking this supplement.
Therefore no formal recommendation can be issued regarding concomitant the use of these agents andthe potential risks of haemorrhage with anti-platelet and anticoagulant agents in ponatinib treated patients need to be considered.
Aspirin(blood thinner): A 1986 in vitro and ex vivo study published in the journal, Arzneimittelforschung,found that curcumin has anti-platelet and prostacyclin modulating effects compared to aspirin, indicating it may have value in patients prone to vascular thrombosis and requiring anti-arthritis therapy.
Caution is advised with treatment of patients most at risk of developing gastrointestinal complications: those with neutropenia, the elderly,concomitant use of NSAIDs, anti-platelet therapy or anti-coagulants, and patients with a prior history of pelvic radiotherapy or gastrointestinal disease, such as ulceration and GI bleeding.